Orphazyme: shares volatile ahead of FDA decision

Strategic Partners A/S

17/06/2021 20:51

(Updates trading prices)
** U.S.-listed shares in Orphazyme  ORPHA.CO   ORPH.O  were down
11.0% at $14.42 as volume soared in volatile session on
Thursday, as the Danish biopharma awaits the U.S. FDA's decision
on its genetic disorder drug  
    ** ORPHA, which was halted for volatility at least once
during the U.S. session, traded between low of $12.91 and high
of $18.45 with volume 3.6 times 10-DMA  
    ** FDA is set to decide on whether to approve the co's lead
candidate, arimoclomol, to treat Niemann-Pick Disease Type C
(NPC)  urn:newsml:reuters.com:*:nL3N2NY3OL
    ** ORPH, whose U.S. shares have been hugely volatile since
June 10 when it rose 301.5% in a single day, has attracted the
attention of individual investors on social media investing
forums such as Reddit's WallStreetBets  urn:newsml:reuters.com:*:nL5N2NW4IH
    ** In the European session, it had been the top performer on
the Copenhagen all-share index on Thurs  .OMXCPI 
    ** It's U.S.-listed shares  ORPH.O  closed about 61% higher
on Wed  urn:newsml:reuters.com:*:nL3N2NY3OL 

 (Reporting by Paulina Cwikowska and Sinéad Carew)
 ((paulina.cwikowska@tr.com))